A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

NCT06750094 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

700

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Neoplasms

Interventions

BIOLOGICAL: Amivantamab
BIOLOGICAL: Cetuximab
BIOLOGICAL: Bevacizumab
DRUG: 5-fluorouracil
DRUG: Leucovorin calcium/Levoleucovorin
DRUG: Irinotecan

Sponsor

Janssen Research & Development, LLC